Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VKTX Stock Forecast 2026-2027
$28.75
Current Price
$3.34B
Market Cap
Buy 18
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to VKTX Price Targets
+334.8%
To High Target of $125.00
+230.4%
To Median Target of $95.00
+18.3%
To Low Target of $34.00
VKTX Price Momentum
+1.1%
1 Week Change
-9.3%
1 Month Change
+10.2%
1 Year Change
-18.3%
Year-to-Date Change
-33.4%
From 52W High of $43.15
+25.2%
From 52W Low of $22.96
📊 TOP ANALYST CALLS
Did VKTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Viking Therapeutics is one of their latest high-conviction picks.
Latest VKTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, VKTX has a bullish consensus with a median price target of $95.00 (ranging from $34.00 to $125.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $28.75, the median forecast implies a 230.4% upside. This outlook is supported by 18 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VKTX Analyst Ratings
18
Buy
2
Hold
0
Sell
VKTX Price Target Range
Low
$34.00
Average
$95.00
High
$125.00
Current: $28.75
Latest VKTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VKTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 28, 2026 | Lake Street | Daniel Brims | Buy | Initiates | $89.00 |
| May 1, 2026 | BTIG | Buy | Reiterates | $N/A | |
| Apr 30, 2026 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 12, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Oct 29, 2025 | Canaccord Genuity | Buy | Initiates | $N/A | |
| Oct 24, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Oct 23, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Sep 29, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 22, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Aug 19, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 24, 2025 | Raymond James | Strong Buy | Maintains | $N/A | |
| Jul 24, 2025 | Citigroup | Neutral | Maintains | $N/A | |
| Jun 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 28, 2025 | Cantor Fitzgerald | Overweight | Initiates | $N/A | |
| Apr 28, 2025 | Truist Securities | Buy | Reiterates | $N/A | |
| Apr 24, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Apr 24, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 17, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Apr 8, 2025 | Goldman Sachs | Neutral | Initiates | $N/A |
Viking Therapeutics Inc. (VKTX) Competitors
The following stocks are similar to Viking Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VKTX
Viking Therapeutics
mkt cap
3.30B
Viking Therapeutics Inc. (VKTX) Financial Data
Viking Therapeutics Inc. has a market capitalization of $3.34B with a P/E ratio of -9.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -70.0%.
Valuation Metrics
Market Cap
$3.34B
Enterprise Value
$2.62B
P/E Ratio
-9.0x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+18.1%
Current Ratio
5.7x
Debt/Equity
0.0x
ROE
-70.0%
ROA
-42.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Viking Therapeutics Inc. (VKTX) Business Model
About Viking Therapeutics Inc.
What They Do
Develops therapies for metabolic and endocrine disorders.
Business Model
Viking Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies that target metabolic and endocrine disorders. The company generates revenue through the advancement of its drug candidates, particularly by progressing them through clinical trials and seeking regulatory approvals, potentially leading to partnerships or sales of successful therapies.
Additional Information
Viking's lead program, VK2735, is currently in Phase 3 trials for obesity, and it also has other candidates targeting metabolic conditions, including VK2809 for non-alcoholic steatohepatitis. The company is headquartered in San Diego, California, and aims to leverage its expertise in metabolic biology to address significant unmet medical needs in this field.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
59
CEO
Dr. Brian Lian Ph.D.
Country
United States
IPO Year
2015
Website
www.vikingtherapeutics.comViking Therapeutics Inc. (VKTX) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $27.73, marking a -5.13% move from the previous day.
Jun 10, 2026
By Zacks Equity Research
Tale of the Tape
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Jun 10, 2026
By Sanghamitra Saha
ETF News and Commentary
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
Jun 09, 2026
By Ahan Chakraborty
Analyst Blog
Latest News
Quick Summary
Viking is advancing candidates in the weight loss drug market, with its lead candidate currently in late-stage studies.
Why It Matters
Viking's late-stage candidates in the growing weight loss drug market could lead to significant revenue opportunities, impacting stock performance and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Viking Therapeutics (VKTX) appointed Dr. Hubert C. Chen as a leader, enhancing its focus on developing therapies for metabolic and endocrine disorders.
Why It Matters
Hubert C. Chen's appointment as a leader at Viking Therapeutics signals potential advancements in their drug development, which could influence stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The global obesity drug market may reach $150 billion by 2035. Viking Therapeutics is developing both a pill and an injectable for weight loss.
Why It Matters
The projected $150 billion market for obesity drugs highlights significant growth potential, making Viking Therapeutics' developments attractive for investors seeking opportunities in emerging health sectors.
Source: The Motley Fool
Market Sentiment:
Positive
Viking Therapeutics, Inc. (VKTX) Falls More Steeply Than Broader Market: What Investors Need to Know
3 days ago
Quick Summary
Viking Therapeutics, Inc. (VKTX) closed at $27.73, down 5.13% from the previous trading session.
Why It Matters
A 5.13% drop in Viking Therapeutics' stock price signals potential volatility, affecting investor sentiment and possibly indicating underlying issues that may impact future performance.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
GLP-1 drugs are transforming healthcare and consumer markets, prompting ETFs to provide targeted investment opportunities in the growing obesity-drug sector.
Why It Matters
GLP-1 drugs' rise signals growth in obesity treatment, impacting healthcare stocks and ETFs, presenting investment opportunities in a lucrative market trend.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
VK2735, in subcutaneous and oral forms, is approaching Phase 1 maintenance trial results, which could highlight its efficacy advantages over competing oral medications.
Why It Matters
VK2735's dual delivery and potential efficacy advantages could disrupt the market, influencing competitor positioning and investment opportunities. Positive trial results may boost stock prices significantly.
Source: The Motley Fool
Market Sentiment:
Positive
Frequently Asked Questions About VKTX Stock
What is Viking Therapeutics Inc.'s (VKTX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Viking Therapeutics Inc. (VKTX) has a median price target of $95.00. The highest price target is $125.00 and the lowest is $34.00.
Is VKTX stock a good investment in 2026?
According to current analyst ratings, VKTX has 18 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $28.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VKTX stock?
Wall Street analysts predict VKTX stock could reach $95.00 in the next 12 months. This represents a 230.4% increase from the current price of $28.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Viking Therapeutics Inc.'s business model?
Viking Therapeutics operates as a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies that target metabolic and endocrine disorders. The company generates revenue through the advancement of its drug candidates, particularly by progressing them through clinical trials and seeking regulatory approvals, potentially leading to partnerships or sales of successful therapies.
What is the highest forecasted price for VKTX Viking Therapeutics Inc.?
The highest price target for VKTX is $125.00 from at , which represents a 334.8% increase from the current price of $28.75.
What is the lowest forecasted price for VKTX Viking Therapeutics Inc.?
The lowest price target for VKTX is $34.00 from at , which represents a 18.3% increase from the current price of $28.75.
What is the overall VKTX consensus from analysts for Viking Therapeutics Inc.?
The overall analyst consensus for VKTX is bullish. Out of 3 Wall Street analysts, 18 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $95.00.
How accurate are VKTX stock price projections?
Stock price projections, including those for Viking Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 13, 2026 5:08 PM UTC